Arq Inc (ARQ) Q4 2025 Earnings Call Transcript

Why It Matters

The accelerated commercial traction and expanded payer coverage position XEREVE to dominate the branded nonsteroidal topical market, while pipeline advances broaden future growth avenues.

Key Takeaways

• Q4 net product revenue $127.5M, up 84% YoY.
• Full-year revenue guidance raised to $480‑$495M.
• Positive cash flow achieved; quarterly positive cash flow expected 2026.
• XEREVE holds ~45% market share in branded nonsteroidal topicals.
• Medicare Part D access secured for roughly one‑third of beneficiaries.

Pulse Analysis

Arcutis’s Q4 performance underscores the power of a differentiated, nonsteroidal topical in a market still dominated by corticosteroids. By securing single‑step formulary placement with major PBMs and expanding Medicare Part D coverage to roughly one‑third of beneficiaries, the company has removed key barriers to adoption. This access strategy, combined with a 20% increase in the dermatology sales force and a pilot primary‑care team, fuels the 84% YoY revenue surge and supports the raised 2026 guidance. Investors should note that the stable gross‑to‑net ratio in the high‑50s suggests pricing power remains intact despite broader industry rebate pressures.

Beyond commercial execution, Arcutis is leveraging its XEREVE platform to address unmet pediatric needs. The supplemental NDA for XEREVE Cream 0.3% in psoriasis for children aged two to five, along with the INTEGUMENT‑Infant trial showing 58% of infants achieving EASI‑75 at four weeks, positions the firm for label expansions that could unlock additional market share. Early data from Phase II proof‑of‑concept studies in vitiligo and hidradenitis suppurativa further diversify the pipeline, reducing reliance on a single indication and enhancing long‑term valuation.

Financially, the transition to positive operating cash flow marks a pivotal shift from growth‑stage burn to sustainable profitability. With $221.3 million in cash and marketable securities and a manageable $108 million debt load, Arcutis has ample liquidity to fund sales force expansion, ongoing trials, and potential credit facility draws. The combination of robust top‑line growth, disciplined cost management, and a clear roadmap for pipeline advancement suggests the company is well‑positioned to capitalize on the expanding nonsteroidal topical segment and deliver shareholder value in the coming years.